title: Neutralization of five subgenotypes of Enterovirus 71 by Taiwanese human plasma and Taiwanese plasma derived intravenous immunoglobulin.
abstract: Enterovirus 71 (EV71) commonly occurs in children, causing hand, foot and mouth disease (HFMD) in about 29% of patients. Studies have suggested that patients develop meningitis and encephalopathy with a mortality rate of 4-26%. EV71 subgenotypes including B4, B5, C2, C4 and C5 have caused HFMD epidemics in Taiwan. In terms of therapeutical strategy, intravenous immunoglobulin (IVIG) has been shown to improve patient conditions. In this study, the EV71 neutralizing titer was evaluated in 75 human plasmas and 8 lots of Taiwanese plasma derived IVIG. Results showed that human plasmas and IVIG significantly neutralized B4 and C2 subgenotypes. Four percent of human plasma contained neutralizing antibody titer of 1:128 against B4 and C2. Most IVIG lots possessed a median effective dose of over 100 against B4 and C2. IVIG lots had an average neutralizing capacity of 5.60, 0.90, 4.30, 1.12 and 0.77 log10 CCID50/ml against B4, B5, C2, C4 and C5, respectively. In conclusion, effective neutralization of B4 and C2 could be due to their earlier appearance in the EV71 epidemiology timeline of Taiwan. IVIG derived from Taiwanese plasma may be desirable for treatment of patients infected with EV71 of specific subgenotypes.
authors.affiliation: Section of Biologics & Advanced Therapeutic Product Analysis, Division of Research and Analysis, Taiwan Food and Drug Administration, Department of Health, Executive Yuan, Taiwan, ROC.
authors.forename: Chi-Yu
authors.initials: CY
authors.lastname: Wu
authors.forename: Hsiu-Chi
authors.initials: HC
authors.lastname: Wang
authors.forename: Kun-Teng
authors.initials: KT
authors.lastname: Wang
authors.forename: Shu-Ching
authors.initials: SC
authors.lastname: Weng
authors.forename: Wei-Hao
authors.initials: WH
authors.lastname: Chang
authors.forename: Daniel Yang-Chih
authors.initials: DY
authors.lastname: Shih
authors.forename: Chi-Fang
authors.initials: CF
authors.lastname: Lo
authors.forename: Der-Yuan
authors.initials: DY
authors.lastname: Wang
mesh_terms: D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000097:blood / Q000276:immunology*; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D029821:Enterovirus A, Human / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D004769:Enterovirus Infections / Q000097:blood / Q000276:immunology* / Q000517:prevention & control; D005838:Genotype; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000097:blood / Q000276:immunology*; D009500:Neutralization Tests; D013624:Taiwan
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D016756:Immunoglobulins, Intravenous